Elaboration of regulatory approaches to managing the risk of the use of biomedical cell products in the Russian Federation

Download full text PDF
DOI: https://doi.org/10.29296/25419218-2021-05-01
Issue: 
5
Year: 
2021

A.A. Taube(1,2), R.N. Alyautdin(1), V.A. Merkulov(1), E.V. Melnikova1, D.V. Goryachev(1), 1-Research Center for Examination of Medical Products, Ministry of Health of the Russian Federation, 8, Petrovsky Boulevard, Build. 2, Moscow 127051, Russian Federation; 2-Saint Petersburg Chemopharmaceutical University, 14, Prof. Popov St., Saint Petersburg 197376, Russian Federation

Introduction. In recent years, the Russian Federation has created a regulatory framework for putting biomedical cell products (BMCP) into civil circulation. The BMCP market in our country is just beginning to develop, while this market in the EU and the USA is actively providing new opportunities for healthcare and patients. Due to the complexity of the composition, to the individual use, and high cost of these medicines, developers and regulatory authorities face new questions about the management of risks associated with the use of BMCP. Objective: to analyze risk-oriented approaches by foreign regulatory authorities having their practical experience in examining and regulating the circulation of BMCP analogues on the market in order to elaborate national approaches to managing the risk of BMCP usage. Material and methods. The investigation was based on the normative documents regulating the circulation of BMCP analogues in the USA and the EU and the guidelines prepared by regulatory authorities. Logical methods of system analysis and modeling were used in the investigation. Results. The investigators studied the currently developed requirements for risk management at all stages of the BMCP life cycle, starting from the early development stage. The information about the introduced approaches to BMCP risk management is given. The analysis of various regulatory approaches to assessing the risks during BMCP circulation made it possible to propose areas for improving the regulation of BMCP circulation. It showed the necessity of creating separate guidelines for developers of BMCP at all stages of their life cycle, by taking into account the specific risks for each type of BMCP. Conclusion. It is necessary to create and maintain a patient and product traceability system with the necessary detail to ensure quality and establish causal relationships between drugs and incoming signals, as well as between a drug and a patient at all stages of the BMCP life cycle from production to destruction.
Keywords: 
biomedical cell product (BMCP)
medicinal products based on viable human cells
gene therapy
somatic cell therapy
tissue-engineering product
risk-oriented approach
risk management plan
References: 
  1. Sevast'janov V.I. Tehnologii tkanevoj inzhenerii i regenerativnoj meditsiny. Vestnik transplantologii i iskusstvennyh organov. 2014; 16 (3): 93–108. [Sevastianov V.I. Technologies of tissue engineering and regenerative medicine. Russian J. of Transplantology and Artificial Organs. 2014; 16 (3): 93–108 (in Russian)]. DOI:10.15825/1995-1191-2014-3-93-108
  2. Srinivasan N., Kellathur S.N., Lou H.-H. Cell and tissue therapy regulation: worldwide status and harmonization. Biologicals. 2012; 40 (3): 222–4. DOI: 10.1016/j.biologicals.2012.01.004
  3. Vestergaard H.T., D'Apote L., Schneider C.K., Herberts C. The Evolution of Nonclinical Regulatory Science: Advanced Therapy Medicinal Products as a Paradigm. Molekular Therapia. 2013; 21 (9): 1644–8. DOI:10.1038/mt.2013.175
  4. Anastasaki E., Walker A., Bradshaw S. An Update on Clinical And Economic Evidence Requirements for Advanced Therapy Medicinal Products in Europe. 2014; 17 (7): A444. DOI: 10.1016/j.jval.2014.08.1176
  5. Pearce K.F., Hildebrandt M., Greinix H. et al. Regulation of advanced therapy medicinal products in Europe and the role of academia. Cytotherapy. 2014; 16 (3): 289–97. DOI: 10.1016/j.jcyt.2013.08.003
  6. Hanna E., Rémuzat C., Auquier P., Toumi M. Advanced therapy medicinal products: current and future perspectives. J. Mark. Access. Health Policy. 2016; 4 (1): 31036. DOI: 10.3402/jmahp.v4.31036
  7. Salmikangas P., Schuessler-Lenz M., Ruiz S. et al. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective. Adv. Exp. Med. Biol. 2015; 871: 103–30. DOI: 10.1007/978-3-319-18618-4_6
  8. Madeira C., Santhagunam A., Salgueiro J., Cabra J.M.S. Advanced cell therapies for articular cartilage regeneration. Trends in Biotechnology. 2015; 33 (1): 35–42. DOI: 10.1016/j.tibtech.2014.11.003
  9. Ivolgin D.A., Kudlaj D.A. Mezenhimal'nye mul'tipotentnye stromal'nye kletki i onkobezopasnost': dve storony odnoj medali ili obojudoostryj mech (obzor zarubezhnoj literatury). Rossijskij zhurnal detskoj gematologii i onkologii. 2021; 8 (1): 64–84. [Ivolgin D.A., Kudlay D.A. Mesenchymal multipotent stromal cells and cancer safety: two sides of the same coin or a double-edged sword (review of foreign literature). Rossijskij zhurnal detskoj gematologii i onkologii. 2021; 8 (1): 64–84 (in Russian)].
  10. Viganò M., Lugano G., Perucca Orfei C. et al. Autologous Microfragmented Adipose Tissue Reduces the Catabolic and Fibrosis Response in an in vitro model of Tendon Cell Inflammation. Stem. Cells Int. 2019; 5: 5620286. DOI: 10.1155/2019/5620286
  11. Henriques D., Moreira R., Schwamborn J. et al. Successes and Hurdles in Stem Cells Application and Production for Brain Transplantation. Front Neurosci. 2019; 19 (13): 1194. DOI: 10.3389/fnins.2019.01194